Prediction of response to nortriptyline and phenelzine by platelet MAO activity
Thirty-seven depressed patients over the age of 55 were treated for 5-7 weeks with either nortriptyline, a tricyclic antidepressant, or phenelzine, a monoamine oxidase (MAO) inhibitor. Patients' platelet MAO activity was measured following a drug washout period before treatment. Patients with h...
Gespeichert in:
| Veröffentlicht in: | The American journal of psychiatry 1987-03, Vol.144 (3), p.338-340 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 3 |
| container_start_page | 338 |
| container_title | The American journal of psychiatry |
| container_volume | 144 |
| creator | GEORGOTAS, A MCCUE, R. E FRIEDMAN, E COOPER, T |
| description | Thirty-seven depressed patients over the age of 55 were treated for 5-7
weeks with either nortriptyline, a tricyclic antidepressant, or phenelzine,
a monoamine oxidase (MAO) inhibitor. Patients' platelet MAO activity was
measured following a drug washout period before treatment. Patients with
higher MAO activity had a better response to treatment, regardless of which
drug was used. |
| doi_str_mv | 10.1176/ajp.144.3.338 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77431402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1310614425</sourcerecordid><originalsourceid>FETCH-LOGICAL-a407t-715b3d97655c5e4bc1ba041bccfe1f7cbaaa1940367e0692cb4aa0f77224f7083</originalsourceid><addsrcrecordid>eNp10UuLFDEQAOAgyjquHj0KQcWD0GOene7jsviClfGg4C1UZ6oxQ08Sk4ww_nqzzLCI6CkU9VGpByFPOVtzbvo3sEtrrtRarqUc7pEV11J3RojhPlkxxkQ3avntIXlUyq6FTBpxQS7kIHol1YpsPmfceld9DDTONGNJMRSkNdIQc80-1ePiA1IIW5q-Y8Dl1204HWlaoOKClX662lBoJX76enxMHsywFHxyfi_J13dvv1x_6G427z9eX910oJipneF6ktvR9Fo7jWpyfAKm-OTcjHw2bgIAPiome4OsH4WbFACbTZtLzYYN8pK8OtVNOf44YKl274vDZYGA8VCsMUpyxUSDz_-Cu3jIofVmhWBKc6VZQy_-h7jkrG_7Fbqp7qRcjqVknG3Kfg_5aDmzt7ew7Ra2WSttu0Xzz85VD9Met3f6vPyWf3nOQ3GwzBmC8-WODUKMSpvGXp8YpOT_aOyff_4G1eKeDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1310614425</pqid></control><display><type>article</type><title>Prediction of response to nortriptyline and phenelzine by platelet MAO activity</title><source>MEDLINE</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>Periodicals Index Online</source><creator>GEORGOTAS, A ; MCCUE, R. E ; FRIEDMAN, E ; COOPER, T</creator><creatorcontrib>GEORGOTAS, A ; MCCUE, R. E ; FRIEDMAN, E ; COOPER, T</creatorcontrib><description>Thirty-seven depressed patients over the age of 55 were treated for 5-7
weeks with either nortriptyline, a tricyclic antidepressant, or phenelzine,
a monoamine oxidase (MAO) inhibitor. Patients' platelet MAO activity was
measured following a drug washout period before treatment. Patients with
higher MAO activity had a better response to treatment, regardless of which
drug was used.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/ajp.144.3.338</identifier><identifier>PMID: 3826434</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Aged ; Biological and medical sciences ; Blood ; Blood Platelets - enzymology ; Depressive Disorder - blood ; Depressive Disorder - drug therapy ; Depressive Disorder - psychology ; Drugs ; Female ; Humans ; Male ; Medical research ; Medical sciences ; Mental depression ; Middle Aged ; Monoamine Oxidase - blood ; Neuropharmacology ; Nortriptyline - pharmacology ; Nortriptyline - therapeutic use ; Pharmacology. Drug treatments ; Phenelzine - pharmacology ; Phenelzine - therapeutic use ; Probability ; Psychiatric Status Rating Scales ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology</subject><ispartof>The American journal of psychiatry, 1987-03, Vol.144 (3), p.338-340</ispartof><rights>1987 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Mar 1987</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a407t-715b3d97655c5e4bc1ba041bccfe1f7cbaaa1940367e0692cb4aa0f77224f7083</citedby><cites>FETCH-LOGICAL-a407t-715b3d97655c5e4bc1ba041bccfe1f7cbaaa1940367e0692cb4aa0f77224f7083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/ajp.144.3.338$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/ajp.144.3.338$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2846,21608,27846,27901,27902,77533,77534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8229457$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3826434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GEORGOTAS, A</creatorcontrib><creatorcontrib>MCCUE, R. E</creatorcontrib><creatorcontrib>FRIEDMAN, E</creatorcontrib><creatorcontrib>COOPER, T</creatorcontrib><title>Prediction of response to nortriptyline and phenelzine by platelet MAO activity</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>Thirty-seven depressed patients over the age of 55 were treated for 5-7
weeks with either nortriptyline, a tricyclic antidepressant, or phenelzine,
a monoamine oxidase (MAO) inhibitor. Patients' platelet MAO activity was
measured following a drug washout period before treatment. Patients with
higher MAO activity had a better response to treatment, regardless of which
drug was used.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Blood Platelets - enzymology</subject><subject>Depressive Disorder - blood</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - psychology</subject><subject>Drugs</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Monoamine Oxidase - blood</subject><subject>Neuropharmacology</subject><subject>Nortriptyline - pharmacology</subject><subject>Nortriptyline - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenelzine - pharmacology</subject><subject>Phenelzine - therapeutic use</subject><subject>Probability</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNp10UuLFDEQAOAgyjquHj0KQcWD0GOene7jsviClfGg4C1UZ6oxQ08Sk4ww_nqzzLCI6CkU9VGpByFPOVtzbvo3sEtrrtRarqUc7pEV11J3RojhPlkxxkQ3avntIXlUyq6FTBpxQS7kIHol1YpsPmfceld9DDTONGNJMRSkNdIQc80-1ePiA1IIW5q-Y8Dl1204HWlaoOKClX662lBoJX76enxMHsywFHxyfi_J13dvv1x_6G427z9eX910oJipneF6ktvR9Fo7jWpyfAKm-OTcjHw2bgIAPiome4OsH4WbFACbTZtLzYYN8pK8OtVNOf44YKl274vDZYGA8VCsMUpyxUSDz_-Cu3jIofVmhWBKc6VZQy_-h7jkrG_7Fbqp7qRcjqVknG3Kfg_5aDmzt7ew7Ra2WSttu0Xzz85VD9Met3f6vPyWf3nOQ3GwzBmC8-WODUKMSpvGXp8YpOT_aOyff_4G1eKeDA</recordid><startdate>19870301</startdate><enddate>19870301</enddate><creator>GEORGOTAS, A</creator><creator>MCCUE, R. E</creator><creator>FRIEDMAN, E</creator><creator>COOPER, T</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>HAWNG</scope><scope>HBMBR</scope><scope>IBDFT</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>19870301</creationdate><title>Prediction of response to nortriptyline and phenelzine by platelet MAO activity</title><author>GEORGOTAS, A ; MCCUE, R. E ; FRIEDMAN, E ; COOPER, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a407t-715b3d97655c5e4bc1ba041bccfe1f7cbaaa1940367e0692cb4aa0f77224f7083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Blood Platelets - enzymology</topic><topic>Depressive Disorder - blood</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - psychology</topic><topic>Drugs</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Monoamine Oxidase - blood</topic><topic>Neuropharmacology</topic><topic>Nortriptyline - pharmacology</topic><topic>Nortriptyline - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenelzine - pharmacology</topic><topic>Phenelzine - therapeutic use</topic><topic>Probability</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GEORGOTAS, A</creatorcontrib><creatorcontrib>MCCUE, R. E</creatorcontrib><creatorcontrib>FRIEDMAN, E</creatorcontrib><creatorcontrib>COOPER, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Index Online Segment 13</collection><collection>Periodicals Index Online Segment 14</collection><collection>Periodicals Index Online Segment 27</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GEORGOTAS, A</au><au>MCCUE, R. E</au><au>FRIEDMAN, E</au><au>COOPER, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of response to nortriptyline and phenelzine by platelet MAO activity</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>1987-03-01</date><risdate>1987</risdate><volume>144</volume><issue>3</issue><spage>338</spage><epage>340</epage><pages>338-340</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>Thirty-seven depressed patients over the age of 55 were treated for 5-7
weeks with either nortriptyline, a tricyclic antidepressant, or phenelzine,
a monoamine oxidase (MAO) inhibitor. Patients' platelet MAO activity was
measured following a drug washout period before treatment. Patients with
higher MAO activity had a better response to treatment, regardless of which
drug was used.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>3826434</pmid><doi>10.1176/ajp.144.3.338</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-953X |
| ispartof | The American journal of psychiatry, 1987-03, Vol.144 (3), p.338-340 |
| issn | 0002-953X 1535-7228 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77431402 |
| source | MEDLINE; Psychiatry Legacy Collection Online Journals 1844-1996; Periodicals Index Online |
| subjects | Aged Biological and medical sciences Blood Blood Platelets - enzymology Depressive Disorder - blood Depressive Disorder - drug therapy Depressive Disorder - psychology Drugs Female Humans Male Medical research Medical sciences Mental depression Middle Aged Monoamine Oxidase - blood Neuropharmacology Nortriptyline - pharmacology Nortriptyline - therapeutic use Pharmacology. Drug treatments Phenelzine - pharmacology Phenelzine - therapeutic use Probability Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology |
| title | Prediction of response to nortriptyline and phenelzine by platelet MAO activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T17%3A50%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20response%20to%20nortriptyline%20and%20phenelzine%20by%20platelet%20MAO%20activity&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=GEORGOTAS,%20A&rft.date=1987-03-01&rft.volume=144&rft.issue=3&rft.spage=338&rft.epage=340&rft.pages=338-340&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/ajp.144.3.338&rft_dat=%3Cproquest_cross%3E1310614425%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1310614425&rft_id=info:pmid/3826434&rfr_iscdi=true |